CIRSE Emprint Microwave Ablation Registry

Inclusion Criteria: * 18 years or older * Proven colorectal liver metastases either histologically proven or diagnosed by imaging in a patient with known colorectal cancer * Treated with the Emprint or Emprint HP Microwave ablation system * Patient referred to MWA by a multidisciplinary tumour board * Signed informed consent form * Intention to completely treat (ablation, resection, SBRT) all visible disease within 8 weeks * Maximum number of 9 total liver lesions * All liver lesions must be local treatment-naive * Maximum diameter of the largest liver lesion treated with MWA must not exceed 3cm * Maximum diameter of lesions treated surgically may exceed this limitation * Maximum number of 5 lung nodules eligible to be treated * Patients may receive simultaneous liver resection and microwave ablation * Patients may have received previous systemic therapy * Patients must not have received surgical resection or thermal ablation for other liver lesions in the last 3 months before inclusion * Patients treated with a liver-first approach may be included if treatment of the primary tumour is planned * If applicable: complete response of treated rectal tumour proven by imaging Exclusion Criteria: * Life expectancy less than 6 months (palliative treatment) * Extrahepatic metastases with the exception of a maximum of 5 lung nodules * Ongoing infection (viral/bacterial) * Patients receiving simultaneous bowel surgery and microwave ablation * Patients receiving simultaneous IRE, RFA, SBRT, Cryoablation, HIFU or other local treatment than resection * Pregnancy * Patients with liver metastases that cannot be completely and safely treated * Active cancers other than CRC * Non-resected primary colon cancer * Advanced liver disease or evidence of liver insufficiency